Cryoport unveils HV3 cryogenic shipping system for advanced therapies

Temperature-controlled supply chain solutions specialist Cryoport has launched a new high-volume cryogenic shipping system.

The Express® Cryogenic shipping system, HV3 for short, is designed to meet the needs of advanced therapies, keeping temperature stable at -150°C and is compliant with airline requirements to allow for air travel.

The HV3 offers additional space for non-temperature sensitive accessories and documentation and improves storage efficiency through the ability to stack and nest the shippers.

Jerrell Shelton, CEO of Cryoport, said, “We are committed to anticipating industry challenges and continuously evolving our solutions to meet the critical needs of our clients and the patients they serve.”

“With the introduction of the Cryoport Express Cryogenic HV3 shipping system, we are improving patient access to vital cell therapies in smaller cities and remote areas, which will ultimately improve patient outcomes at large.”

The HV3 is also designed to be used with Cryoport’s Safepak® System. The Safepak® System is a purpose-built solution that utilises non-metallic, soft materials to minimize the effects of vibration and shock during the transport of cell and gene therapies.

According to Nova One Advisor, the global cell and gene therapy market size was valued at $18.13bn in 2023 but is expected to reach around $97.33bn in 2033, growing at a CAGR of 18.3% from 2024 to 2033.

The life sciences industry requires a robust shipping system, at cryogenic temperatures that can handle the risks associated with transporting high-value commodities such as advanced therapies. Slight temperature deviations can render the commodity ineffective, and minor physical damage can also damage its usability.

With so much at stake, advanced therapy developers and manufacturers need an advanced packaging system that can maintain consistent temperatures to deliver raw materials, viral vectors, and gene therapies in perfect condition.